Gilead Sciences, Inc. has received conditional marketing authorization from the European Commission (EC) for Seladelpar for the treatment of primary biliary cholangitis (PBC) ...

Gilead Sciences (GILD) said on Friday that the European Commission (EC) granted conditional marketing authorization for ...

Gilead Sciences’ seladelpar has won conditional marketing authorization to treat primary biliary cholangitis (PBC) alongside ...

Sciences announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted conditional marketing ...

(HealthDay News) — In a clinical report issued by the American Academy of Pediatrics and published online Feb. 18 in Pediatrics, recommendations are presented to assist primary care providers in ...

A progressive liver condition affects thousands of Americans, but early symptoms are often dismissed as everyday ailments. Learn the critical warning signs of Primary biliary cholangitis (PBC) and ...

COUR Pharmaceuticals has been around a while, but not until last year did the company solidify behind its ultimate mission ...

NORTHAMPTON, MA / ACCESS Newswire / February 19, 2025 / Take a spin through the latest in Gilead's science and innovation in our new series, The Centrifuge Sessions. Today we sit down with D. Barry ...

Question: I recently noticed a strange growth on my bottom eyelid. It isn’t coming out of a hair follicle, and it isn’t a ...

GILD's strong HIV portfolio should maintain momentum for the company. The guidance for 2025 is impressive. We believe there ...

Bile duct disorders can lead to serious complications if left untreated, but early diagnosis and proper management can prevent long-term damage, a doctor states. READ ON to find out more.